On November 7, 2024, Imunon, Inc. (IMNN) announced financial results for the third quarter of 2024 and provided a business update. Following release of positive topline results from the OVATION 2 trial of IMNN-001, which showed an overall survival improvement of 11.1 months compared to standard of care treatment, the company will be meeting with the FDA this month as it finalizes designs of the planned Phase 3 registrational study of IMNN-001 in patients with advanced ovarian cancer. We continue to anticipate the 500-patient trial initiating in the first quarter of 2025. In addition, we anticipate results from the Phase 1 trial of IMNN-101 before the end of 2024 as the company is looking to enter into a partnership to continue its development.
